Has announced that it has filed its initial IND application with the U.

Co-inventor of the tkRNAi technology, Johannes Fruehauf, M.D., will support the forthcoming clinical trial through a consultancy arrangement mainly because vice president of medical affairs. .. Cequent Pharmaceuticals proposes the first test of an orally administered RNA interference drug in humans Cequent Pharmaceuticals, a pioneer in the development of novel products to deliver RNAi-based treatments to avoid and treat individual disease, has announced that it has filed its initial IND application with the U.S. Meals and Drug Administration . CEQ508, an orally administered tkRNAi medication candidate, targets beta-catenin, a key oncogene implicated in the formation of colonic polyps and in the progression of polyps to colorectal cancers.The researchers from the University of Leicester in the united kingdom say their results reaffirm that doctors should not use antibiotics for premature labour when the mother’s water is normally intact and there is no infection. Their study viewed women at risk of premature labour who had no signs of an infection and the researchers say the problem is not really the antibiotics but instead the situation where the antibiotics are given. The analysis found 35 situations of cerebral palsy in 769 children of women without early damaged waters who were given antibiotics. This compared with 12 cases among 735 children of women not really given the drugs.